An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement.

Trial Profile

An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2012

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals
  • Most Recent Events

    • 18 May 2011 Combined results from this and two other trials (NCT00612534 and NCT00718081) presented at the 30th Annual Scientific Meeting of the American Pain Society, according to a AcelRx Pharmaceuticals media release.
    • 20 Apr 2010 Actual number of patients and trial centres updated, as reported by an AcelRx Pharmaceuticals media release.
    • 20 Apr 2010 Study results will be presented at the 35th Annual Regional Anesthesia Meeting of the American Society of Regional Anesthesia and Pain, to be held in Toronto, Ontario, Canada on 22-25 April 2010, as reported by an AcelRx Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top